Drug Topics

OCTOBER 29, 2024

The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.

FDA 161

FDA 161

Pharmacy Times

OCTOBER 29, 2024

The STRIPE Double Helix Awards celebrate individuals and organizations that have made exceptional contributions to the field of pharmacogenomics.

149

149

STAT

OCTOBER 29, 2024

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said.

Vaccines 145

Vaccines Immunization 145

Fierce Healthcare

OCTOBER 29, 2024

Walgreens is conducting another round of layoffs as the drugstore giant looks to significantly cut costs and improve its financial performance. It's the third round of cuts in 2024. | Walgreens is conducting another round of layoffs as the drugstore giant looks to significantly cut costs and turnaround its financial performance.

132

132

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

OCTOBER 29, 2024

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

132

132

Fierce Healthcare

OCTOBER 29, 2024

Accountable care organizations saved Medicare $2.1 billion, the largest yearly savings in program history, in 2023, the Centers for Medicare & Medicaid Services revealed on Tuesday. | Accountable care organizations (ACOs) saved Medicare $2.1 billion, the largest yearly savings in program history, in 2023, the Centers for Medicare & Medicaid Services (CMS) revealed Oct. 29.

131

131

STAT

OCTOBER 29, 2024

Twenty years ago, a respected colleague asked me to perform a “poop transplant” on a local schoolteacher with multiply recurrent C. difficile infection.  I was incredulous and skeptical, but my colleague (a friend but a forceful one) persisted until I ultimately acquiesced.  Soon I was in a hazmat suit blenderizing stool and performing my first (subsequently named) fecal microbiota transplant, or FMT.

FDA 127

FDA 127

Fierce Healthcare

OCTOBER 29, 2024

Oracle Health plans to release a new electronic health record platform in 2025, the company announced Tuesday. | Oracle Health executive Seema Verma stressed that the next-gen EHR platform is not a "refurbished Cerner EHR." "You can’t bolt new innovation onto something built in the 1990s," she said.

Cerner 125

Cerner 125

STAT

OCTOBER 29, 2024

As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States. U.S. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China.

132

132

Pharmacy Times

OCTOBER 29, 2024

The accelerated approval comes after 48-week major molecular response rate data.

FDA 121

FDA 121

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 29, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Hello and happy Tuesday, D.C. Diagnosis readers! We are one week from Election Day; I probably don’t need to remind you.

121

121

Fierce Pharma

OCTOBER 29, 2024

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. | Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.

120

120

Fierce Healthcare

OCTOBER 29, 2024

Athenahealth will release a product that allows clinicians in the same practice to choose which AI ambient scribe they want to use and easily use it in their workflow. | Athenahealth partnered with Suki AI and iScribe to let clinicians choose their preferred scribe without locking them into a long-term contract.

119

119

Fierce Pharma

OCTOBER 29, 2024

Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | The company is projecting yearly sales of $61 billion to $64 billion in a $1.5 billion boost from previous forecasts.

119

119

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

OCTOBER 29, 2024

Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose “clear, anticompetitive risks.” McKesson, Cardinal Health, and Cencora are the three dominant wholesalers that distribute drugs and medical products.

108

108

Fierce Pharma

OCTOBER 29, 2024

Modified dosing regimen of Eli Lilly's Alzheimer's drug leads to significant reduction in brain swelling kdunleavy Tue, 10/29/2024 - 15:25

115

115

STAT

OCTOBER 29, 2024

The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program. As the director of Medicare, my team and I worked thoughtfully and diligently to stand up the program — on time and successfully.

108

108

pharmaphorum

OCTOBER 29, 2024

UK government confirms £1.8bn funding boost to NHS to cut waiting lists, including £1.

115

115

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

OCTOBER 29, 2024

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show. But it’s unclear whether the new dosing schedule, if approved by regulators, will convince doctors that the treatment is safer for patients. At 24 weeks of a Phase 3b trial, 24% of those taking the standard regimen experienced a side effect called ARIA-E, a kind of brain swelling.

116

116

Pharmacy Times

OCTOBER 29, 2024

The approval marks the first and only abuse-deterrent immediate release oxycodone formulation.

FDA 114

FDA 114

Drug Topics

OCTOBER 29, 2024

Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Chron’s disease.

112

112

Pharmacy Times

OCTOBER 29, 2024

Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.

111

111

Drug Topics

OCTOBER 29, 2024

Trent Thiede, PharmD, MBA, president of PAAS National, discusses best practices that pharmacy teams can implement to proactively prevent audit issues before they arise.

112

112

pharmaphorum

OCTOBER 29, 2024

An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking.On the plus side, the health technology assessment (HTA) body has concluded that tools to help people manage their antihypertensive drug treatment can deliver benefits in reduced blood pressure.

People Management 107

People Management 107

Pharmaceutical Technology

OCTOBER 29, 2024

The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.

105

105

pharmaphorum

OCTOBER 29, 2024

Pfizer CEO Albert Bourla hit back at activist investor Starboard Value, saying measures to reset the pharma group are already well in hand

106

106

Fierce Pharma

OCTOBER 29, 2024

The FDA has approved the first abuse-deterrent, immediate-release, 10 mg opioid tablet for pain management. The drug, Roxybond, has been approved in other dosages.

Dosage 104

Dosage FDA 104

pharmaphorum

OCTOBER 29, 2024

AbbVie agrees a $1.4bn cash deal to acquire Aliada Therapeutics, adding another anti-amyloid antibody to its Alzheimer's pipeline.

105

105

Drug Topics

OCTOBER 29, 2024

Scott Biggs, Director of Supplier Services at IQVIA, discussed pharmacy trends within the industry and how pharmacists can stay ahead of them.

98

98

pharmaphorum

OCTOBER 29, 2024

Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.In June, the cost-effectiveness agency cleared the use of the BCMAxCD3 bispecific antibody with 'optimised guidance' that allowed it to be used for a narrower range of patients than was covered by the approved label for the drug.

Labelling 105

Labelling 105

Drug Topics

OCTOBER 29, 2024

A.J. Lipka, Business Development Lead of Network Growth at Outcomes, discussed the impact of pharmacy-sponsored programming.

98

98

Fierce Pharma

OCTOBER 29, 2024

As the 2024 U.S. | This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

98

98

Outsourcing Pharma

OCTOBER 29, 2024

Anu Codaty, VP of global marketing and strategy at Aldevron, is blazing trails in biotech, inspired by a family legacy in medicine and driven to create life-changing therapies.

94

94